Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant reduction in the risk of disease progression or death in patients with previously ...

Jason Foster, CEO of Ori Biotech, discusses the difficulties preventing more widespread adoption of these advanced therapies.

A new offering in collaboration with Progyny, Inc makes fertility/family-building services more accessible and equitable.

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas. With the start of the annual JP Morgan ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco. Over the past two years, the life sciences industry has seemingly fully embraced ...

The technology is part of a larger platform that provides a variety of AI-powered services. As people in the industry become more comfortable with the technology, AI is being used to find potential ...

Johnson & Johnson (J&J) announced that it has acquired Intra-Cellular Therapies, a biopharmaceutical company. According to the company, the acquisition includes Caplyta (lumateperone), a once-daily ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% complete response in patients with Bacillus Calmette-Guérin-unresponsive ...